



ASX release

7 July 2010

Second positive Medicare coverage ruling in Michigan
- Reinforces previous judgment requiring plan to cover SphygmoCor System

AtCor Medical (ASX:ACG), the developer and marketer of the SphygmoCor® system, which measures central blood pressures and arterial stiffness non-invasively, today announced a second positive case ruling by an Administrative Law Judge for the Centers for Medicare and Medicaid Services. Specifically, the judge disagreed with the findings of a Medicare health plan assessment in the state of Michigan that the SphygmoCor technology is experimental and ruled that the plan must provide coverage for use of the SphygmoCor System.

As part of his ruling, the judge found that “a growing body of scholarship in the field of medicine establishes that SphygmoCor is both safe and effective, is generally accepted by the medical community and is supported by sound medical evidence based on scientific data or research studies published in peer reviewed medical journals worldwide”

Medicare is the US Government health plan for people over age 65 and those with disabilities. It covers over 45 million Americans and is administered primarily by private contractors on a state or regional basis. The Michigan Medicare carrier is one of the largest Medicare contractors, covering over 5 million lives across four states. “The judge’s ruling validates what is already known and recognised by physicians,” said Duncan Ross, AtCor Medical President and CEO. “Non-invasive central blood pressure assessment enables superior patient management and outcomes, particularly in patients whose blood pressure does not respond to standard treatment.”

A physician used the SphygmoCor System for drug therapy selection and guidance during treatment of a high-risk patient with an extensive history of hypertension and chronic kidney diseases. The patient’s blood pressure was previously uncontrolled using standard brachial cuff blood pressure.

Previously, a number of private health plans have reimbursed physicians for SphygmoCor assessments using an unlisted cardiovascular services code. AtCor Medical continues to drive clinical adoption through local reimbursement decisions and the company remains on track to file for a CPT (Common Procedural Terminology) code specific to central blood pressure assessment as early as November 2010.

About AtCor Medical

AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central blood pressure non-invasively. The company's SphygmoCor system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring. More than 2,100 SphygmoCor systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company's technology has been featured in hundreds of peer-reviewed studies published in leading medical journals. AtCor has operations in Australia, the United States, and Europe. For further information, please visit our web site at www.atcormedical.com.

For further information, please contact:

Duncan Ross – AtCor Medical CEO
+1 (630) 228 8873

Peter Manley – AtCor Medical CFO
+61 (2) 9874 8761

Media enquiries to:

Ashley Rambukwella – Financial &
Corporate Relations
Ph: +61 (2) 8264 1004/ m. 0407 231 282 or
a.rambukwella@fcr.com.au